CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for 23andMe Holding Co. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

23andMe Holding Co.
349 Oyster Point Boulevard
Phone: (650) 938-6300p:650 938-6300 SOUTH SAN FRANCISCO, CA  94080  United States Ticker: MEME
Business Summary
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024YesYes---

Industries
SIC Code Description
8071 Medical laboratories
8731 Commercial physical and biological research
6794 Patent owners and lessors

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer, Co-Founder AnneWojcicki 50 1/1/2006 1/1/2006
Chief Financial and Accounting Officer JoeSelsavage 61 1/1/2023 9/1/2022
Lead Independent Director Mark E.Jensen 73 10/28/2024 10/28/2024
Independent Director AndreFernandez 55 10/28/2024 10/28/2024
Independent Director JimFrankola 59 10/28/2024 10/28/2024

Subsidiaries
Business Name Address City State/Province Country
LEMONAID HEALTH INC 870 MARKET ST SAN FRANCISCO CA US
23andMe, Inc. 349 Oyster Point Boulevard South San Francisco CA United States
LEMONAID PHARMACY 1701 MACKLIND AVE STE 300B SAINT LOUIS MO
LEMONAID COMMUNITY PHARMACY INC 7580 WATSON RD SHREWSBURY MO
LPRXONE LLC 1701 MACKLIND AVE STE 300 ST LOUIS MO

Business Names
Business Name
23andMe Pharmacy Holdings, Inc.
23andMe, Inc.
CureTogether, Inc.
13 additional Business Names available in full report.

General Information
Number of Employees: 560 (As of 3/31/2024)
Outstanding Shares: 26,117,997 (As of 10/31/2024)
Shareholders: 260
Stock Exchange: NASD
Federal Tax Id: 871240344
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024